{"id":506327,"date":"2026-05-28T04:18:46","date_gmt":"2026-05-28T04:18:46","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/506327\/"},"modified":"2026-05-28T04:18:46","modified_gmt":"2026-05-28T04:18:46","slug":"bofa-cuts-pt-on-boston-scientific-corporation-bsx-over-worries-for-medtech","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/506327\/","title":{"rendered":"BofA Cuts PT on Boston Scientific Corporation (BSX) Over Worries for Medtech"},"content":{"rendered":"\n

Boston Scientific Corporation (NYSE:BSX<\/a>) is one of the best medical stocks to invest in according to billionaires<\/strong><\/a>. BofA cut the price target on Boston Scientific Corporation (NYSE:BSX) to $68 from $105 on May 18, reaffirming a Buy rating on the shares. The firm told investors that after having hosted 34 medtech companies last week in Las Vegas, it updated several price targets for \u201cthe new reality of medtech valuations\u201d in a year of few product cycles, inflation kicking up post-war, ACA, and utilization worries, and \u201cdata centers over healthcare\u201d.<\/p>\n

\"Baird Baird Maintains Bullish View on Boston Scientific (BSX) Despite Lower Target <\/p>\n

In another development, Argus cut the price target on Boston Scientific Corporation (NYSE:BSX) to $95 from $115 on April 27, reaffirming a Buy rating on the shares. The rating update came after the company\u2019s fiscal Q1 earnings and guidance cut, with the firm telling investors in a research note that the stock has recently underperformed the broader market. However, it added that the company remains well-positioned in high-growth areas such as cardiovascular, electrophysiology, and neuromodulation, with the management setting more achievable objectives by cutting its outlook. Argus believes that Boston Scientific Corporation\u2019s (NYSE:BSX) price weakness creates a buying opportunity.<\/p>\n

Boston Scientific Corporation (NYSE:BSX) manufactures, develops, and markets medical devices used in interventional medical procedures. Its operations are divided into Cardiovascular and MedSurg segments. The Cardiovascular segment covers Cardiology and Peripheral Interventions, while the MedSurg segment comprises Urology, Endoscopy, and Neuromodulation.<\/p>\n

While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock<\/strong><\/a>.<\/p>\n

READ NEXT: <\/strong>15 Stocks That Will Make You Rich in 10 Years<\/strong><\/a> AND <\/strong>12 Best Stocks That Will Always Grow<\/strong><\/a>.<\/strong><\/p>\n

Disclosure: None. Follow Insider Monkey on Google News<\/strong><\/a>.<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"Boston Scientific Corporation (NYSE:BSX) is one of the best medical stocks to invest in according to billionaires. BofA…\n","protected":false},"author":2,"featured_media":506328,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[73],"tags":[51707,77362,79,18,19,17,22425,62906],"class_list":["post-506327","post","type-post","status-publish","format-standard","has-post-thumbnail","category-business","tag-bofa","tag-boston-scientific-corporation","tag-business","tag-eire","tag-ie","tag-ireland","tag-price-target","tag-price-targets"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/116650279372473768","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/506327","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=506327"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/506327\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/506328"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=506327"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=506327"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=506327"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}